RNAi & siRNA Licensing Deal Benchmarks
Market Analysis
RNA interference therapeutics have matured into a validated modality with multiple approved products and a deep clinical pipeline. Phase 2 RNAi/siRNA deals achieve a median total deal value of $1.6B, with upfront payments ranging from $141M to $358M. The Alnylam platform validation and GalNAc-conjugate delivery revolution have transformed RNAi from a struggling modality into a predictable, scalable drug development engine.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for an RNAi/siRNA licensing deal?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating